| Followers | 269 |
| Posts | 30474 |
| Boards Moderated | 0 |
| Alias Born | 08/26/2015 |
Saturday, October 29, 2016 9:02:36 AM
I always thought it had great potential. In fact I had gone all in and mAde
Every rookie mistake there was including not selling. My issue was the lack of transparency and delivery of data that Brought into question all the concerns I had disregarded previously about, size of trial, the fact that it's open, the fact that people from the pran trial were used for the avxl trial. Today I honestly have no idea where it goes because the data, power of the study( we are down to 7 people donezpeil naive) and the lack of transparency with regard to the company makes it too risky for me. I don't trade big boards so traders bought at 2.50 and sold 3.50. I did not. Dilution brings avxl to $1.80.
If you like big board bios. Keeping a substantial position in avxl seems reasonable with regard to science. 3-71 shows greater promise. But that is a long way out. And too much can happen over time. I hope that the longs are right and partnership is announced and everyone I know is made whole and then some. But objectively for me other than a small position and taking out my original capital on the first big bounce which is simply good capital preservation, I await clarity. I don't mind buying higher once that is given. Just my strategy as of now.
Every rookie mistake there was including not selling. My issue was the lack of transparency and delivery of data that Brought into question all the concerns I had disregarded previously about, size of trial, the fact that it's open, the fact that people from the pran trial were used for the avxl trial. Today I honestly have no idea where it goes because the data, power of the study( we are down to 7 people donezpeil naive) and the lack of transparency with regard to the company makes it too risky for me. I don't trade big boards so traders bought at 2.50 and sold 3.50. I did not. Dilution brings avxl to $1.80.
If you like big board bios. Keeping a substantial position in avxl seems reasonable with regard to science. 3-71 shows greater promise. But that is a long way out. And too much can happen over time. I hope that the longs are right and partnership is announced and everyone I know is made whole and then some. But objectively for me other than a small position and taking out my original capital on the first big bounce which is simply good capital preservation, I await clarity. I don't mind buying higher once that is given. Just my strategy as of now.
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
